Cancer-Killing virus combined with keytruda shows promise in stubborn tumors
NCT ID NCT06340711
First seen Apr 25, 2026 · Last updated Jun 22, 2026 · Updated 11 times
Summary
This phase 2 study tests a new approach for people with advanced stomach, esophageal, or gastroesophageal junction cancer that is either PD-L1-negative or has stopped responding to immunotherapy. Participants receive injections of a cancer-killing virus (OBP-301) directly into their tumor during a scope procedure, plus infusions of the immunotherapy drug pembrolizumab (Keytruda). The goal is to see if this combination is safe and effective in shrinking tumors or controlling the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Abramson Cancer Center of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Weill Cornell Medicine/NewYork-Presbyterian Hospital
RECRUITINGNew York, New York, 10065, United States
Contact Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OBP-301 (a virus injected into the tumor) and pembrolizumab (Keytruda, an immunotherapy drug)
What this could lead to
If it works, this combination could offer a new treatment option for people with hard-to-treat stomach or esophageal cancers that don't respond to standard immunotherapy.
What could go wrong
This is a small, early-phase trial with only 27 participants, so results may not apply to everyone. The virus injection requires a scope procedure, and side effects from both drugs are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.